P

Philips

Makes medical devices and personal health products

Global 3PP Supply Chain Leader

Full-TimeUpdated on 10/21/2026
PLN314.9k - PLN521.7k+ Annual incentive
Expert
Bachelor's, Master's
Łódź, Poland+1 moreMore locations: Panama City, Panamá Province, Panama
HybridOffice-based teams work in person at least 3 days per week.
Operations & LogisticsSupply Chain Management

About the job

Requirements
  • A Bachelor's or Master's degree in Supply Chain Management, Operations, Business, Engineering, or a related discipline.
  • 12+ years of progressive leadership experience in global supply chain, procurement, commercial operations, external manufacturing, planning, fulfillment, or business transformation, including responsibility for complex global third-party networks.
  • Demonstrated experience leading strategic supplier partnerships and negotiations, supplier performance, cost productivity, and commercial-performance improvement.
  • Deep end-to-end knowledge of order management, procurement, demand and supply planning, inventory, fulfillment, distribution, and customer delivery.
  • Experience leading cross-functional organizations across Commercial, S&OP, Procurement, Product Management, PLM, Quality, Regulatory Affairs, Engineering, Finance, IT, and regional operations to achieve business and operational objectives.
  • Experience with SAP/ERP, EDI, workflow automation, digital commerce, performance analytics, and control-tower or supply-chain visibility capabilities.
  • Strong financial acumen, including business-case development, margin, working capital, productivity, cost-to-serve, and benefits realization.
  • Executive-level leadership capability to influence senior stakeholders, develop high-performing teams, and operate effectively in a global matrix organization.
  • Ability to perform the minimum physical, cognitive, and environmental job requirements, with or without reasonable accommodation.
Responsibilities
  • Define and execute the global 3PP strategy, target operating model, governance, organization design, and multi-year transformation roadmap, establishing decision rights, performance routines, and global standards across regions and functions.
  • Own the global operational and commercial performance of the 3PP network, including service, quality, cost, delivery, responsiveness, margin, working capital, and customer experience.
  • Lead strategic supplier relationships and, in partnership with Procurement, shape supplier negotiations, commercial terms, sourcing strategy, onboarding, cost-productivity programs, contract compliance, and supplier-performance improvement plans.
  • Lead the global buying and planning organization supporting 3PP, partnering with regional S&OP teams, Procurement, and strategic suppliers to align demand forecasts with supply, capacity, inventory, purchase orders, and fulfillment plans, and proactively mitigate supply risks.
  • Own end-to-end 3PP order fulfillment, from demand signal and order orchestration through supplier purchase-order execution, inventory visibility, fulfillment, delivery, invoicing readiness, and customer experience.
  • Drive 3PP revenue growth, gross-margin improvement, product availability, and digital/eStore enablement in partnership with Commercial and Product Management.
  • Lead cross-functional readiness for product onboarding, new-product introductions, product transfers, engineering changes, obsolescence, and product lifecycle management, ensuring regulatory compliance, successful commercialization, and uninterrupted customer supply.
  • Transform and evolve the global 3PP operating and distribution network through agile fulfillment strategies, optimized inventory positioning, resilient supply-chain design, and continuous improvement.
  • Sponsor the SmartHub digital roadmap, including SAP/ERP integration, EDI, supplier connectivity, control-tower visibility, sales-order orchestration, workflow automation, dashboards, and data-driven performance management.
  • Lead the future integration of TopKal into the 3PP operating model and establish governance for light-touch factory-supported offerings.
  • Own the 3PP business case and benefits realization, including supplier savings, productivity, inventory and working-capital reduction, cost-to-serve reduction, revenue growth, gross-margin improvement, and EBITDA benefits.
  • Build a high-performing global team and matrixed stakeholder network, fostering accountability, collaboration, innovation, and data-driven decision making.

About the company

Philips makes medical equipment and software for hospitals and care providers, along with personal health products for consumers. Its hospital portfolio spans MRI and CT scanners, ultrasound, image-guided treatment systems and patient monitors, while Sonicare and Avent cover oral health and baby care. Clinical software connects medical images and patient data across care teams, and the company earns revenue from equipment, software, maintenance and consumer product sales. It works with health systems through long-term technology and service partnerships, including solutions for care at home. Founded in 1891, Philips is headquartered in Amsterdam, the Netherlands.

Company Size

10,001+

Company Stage

Acquired

Total Funding

$164.7M

Headquarters

Murrysville, Pennsylvania

Founded

1891

Get referred to Philips

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand improved: Philips reported 4% comparable group sales growth for Q2 2026 in July 2026.
  • Software expertise has room to develop: software and data science comprised about half Philips' research effort in 2025.
  • Manufacturing expansion has backing: Philips reiterated a $150 million North American investment plan in February 2026.

What critics are saying

  • US sleep-device sales remain restricted: Philips Respironics must meet consent-decree requirements before resuming new sleep-therapy device sales.
  • Underlying earnings weakened: Philips' July 2026 report shows Q2 adjusted earnings fell slightly excluding its US tariff refund.
  • Central teams face cost pressure: February 2026 plans target 15% to 20% lower central-function costs at Philips.

What makes Philips unique

  • MRI avoids helium refills: Philips says its sealed BlueSeal magnets use seven liters rather than conventional systems' 1,500.
  • Inventions form a substantial asset base: Philips reports 53,000 patent rights across its technology portfolio.
  • The employer's name spans independent businesses: Philips licenses its brands across multiple product categories to outside partners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Unlimited Paid Time Off
  • Health Savings Account/Flexible Spending Account

Company News

PR Newswire
May 28th, 2026
Remote patient monitoring market to reach $117.9B by 2033 amid digital healthcare transformation

The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

YourLawyer.com
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.